ArticleMolecular cancer therapeutics2025

Preclinical Characterization of XB002, an Anti-Tissue Factor Antibody-Drug Conjugate for the Treatment of Solid Tumors.

Seema Kantak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.